Aurobindo Pharma Key Ratios
NSE: AUROPHARMA | BSE: 524804
₹1,645.30
As on 28-Aug-2026IST
Market cap
₹95,225 Cr
Revenue (TTM)
₹34,935 Cr
P/E Ratio
25.6
P/B Ratio
2.4
Div. Yield
0.2 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 3.35 | 16.30 | 9.09 | 11.11 | 7.31 |
| EBIT | 9.42 | 16.45 | 6.91 | 26.09 | 4.44 |
| Net Profit | 15.05 | 28.51 | 11.59 | 23.14 | 3.01 |
| EPS | 13.13 | 26.37 | 9.76 | 23.83 | -6.76 |
| Book Value | -- | -- | 16.04 | 12.51 | 11.75 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 21.38 | 13.85 | 14.96 | 14.97 | 15.55 |
| Net Margin
| 17.63 | 10.11 | 10.42 | 10.25 | 10.77 |
| Return on equity
| 9.97 | 10.23 | 10.38 | 9.93 | 11.15 |
| Return on Capital
| 11.80 | 12.60 | -- | 12.76 | 14.39 |
| Return on Assets
| 6.57 | 7.00 | 6.86 | 6.64 | 7.54 |
| Debt to Equity (x)
| -- | -- | 0.02 | 0.20 | 0.24 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
12.76
|
14.39
|
13.76
|
9.39
|
|
Peer Median
|
--
|
19.34
|
21.76
|
21.89
|
--
|
ROE
10.38
Lower than Peers by 4.97
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
10.38
|
9.93
|
11.15
|
11.18
|
7.50
|
|
Peer Median
|
15.35
|
16.97
|
17.93
|
16.42
|
--
|
ROA
6.86
Lower than Peers by 3.49
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
6.86
|
6.64
|
7.54
|
7.63
|
5.29
|
|
Peer Median
|
10.35
|
9.88
|
12.81
|
12.32
|
--
|
EBIT Margin
14.96
Lower than Peers by 3.05
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
14.96
|
14.97
|
15.55
|
14.90
|
9.95
|
|
Peer Median
|
18.01
|
18.96
|
18.93
|
21.05
|
--
|
Net Margin
10.42
Lower than Peers by 4.03
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
10.42
|
10.25
|
10.77
|
10.72
|
7.67
|
|
Peer Median
|
14.45
|
13.29
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
7.60
|
8.08
|
7.85
|
6.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
9.09
Lower than Peers by 2.86
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
9.09
|
6.08
|
9.39
|
16.68
|
5.97
|
|
Peer Median
|
11.95
|
12.97
|
10.90
|
13.44
|
--
|
EBIT Growth
6.91
Lower than Peers by 14.69
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
6.91
|
2.14
|
14.16
|
74.67
|
-24.06
|
|
Peer Median
|
21.60
|
15.05
|
15.01
|
23.50
|
--
|
Net Profit Growth
11.59
Lower than Peers by 11.15
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
11.59
|
0.56
|
9.93
|
64.40
|
-27.18
|
|
Peer Median
|
22.73
|
11.89
|
14.80
|
30.12
|
--
|
EPS Growth
9.76
Lower than Peers by 10.27
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
9.76
|
0.54
|
10.83
|
64.62
|
-27.21
|
|
Peer Median
|
20.03
|
12.16
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
16.04
|
9.42
|
11.19
|
9.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.02
Higher than Peers by 0.02
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
0.02
|
0.20
|
0.24
|
0.21
|
0.18
|
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
0.16
|
0.17
|
0.14
|
0.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.81
Lower than Peers by 0.27
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
1.81
|
1.81
|
1.85
|
1.95
|
1.87
|
|
Peer Median
|
2.08
|
1.93
|
1.90
|
2.23
|
--
|
Quick Ratio
1.15
Lower than Peers by 0.39
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
1.15
|
1.15
|
1.13
|
1.14
|
1.13
|
|
Peer Median
|
1.54
|
1.52
|
1.46
|
1.59
|
--
|
Interest Coverage
14.98
Lower than Peers by 4.40
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
14.98
|
14.31
|
12.08
|
16.12
|
19.60
|
|
Peer Median
|
19.38
|
19.95
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
20.31
Lower than Peers by 1.07
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
20.31
|
21.08
|
18.11
|
16.61
|
17.97
|
|
Peer Median
|
21.38
|
19.87
|
21.77
|
20.10
|
--
|
Asset Turnover
0.65
Lower than Peers by 0.08
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
0.65
|
1.32
|
1.38
|
1.44
|
1.40
|
|
Peer Median
|
0.72
|
0.77
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
33.71
|
30.33
|
28.34
|
30.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
59.32
|
58.44
|
55.92
|
57.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
148.20
|
135.14
|
133.88
|
117.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
--
|
-55.17
|
-46.37
|
-49.62
|
-29.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
25.65
Lower than Peers by 8.38
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
25.65
|
21.60
|
19.32
|
20.12
|
15.75
|
|
Peer Median
|
34.03
|
34.29
|
26.81
|
39.85
|
--
|
Price / Book Value
2.45
Lower than Peers by 2.37
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
2.45
|
2.00
|
2.06
|
2.14
|
1.13
|
|
Peer Median
|
4.82
|
5.12
|
4.65
|
6.11
|
--
|
Dividend Yield
0.24
Lower than Peers by 0.26
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
0.24
|
0.31
|
--
|
0.41
|
0.58
|
|
Peer Median
|
0.51
|
0.51
|
0.61
|
0.37
|
--
|
EV/EBITDA
11.97
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
11.97
|
10.02
|
9.31
|
9.98
|
7.27
|
|
Peer Median
|
--
|
30.60
|
27.02
|
34.57
|
--
|
Market Cap
95,225
Higher than Peers by 75,902
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Aurobindo Pharma
|
95,225
|
75,689
|
67,356
|
63,830
|
30,348
|
|
Peer Median
|
19,323
|
17,990
|
20,914
|
25,297
|
--
|